

Agilent Technologies, Inc.
Financial Information Index of Schedules

Financial Statements:	Page
Condensed Consolidated Statements of Operations (Three and Nine Months Ended July 31, 2026 and 2025)	1
Condensed Consolidated Balance Sheets as of July 31, 2026 and October 31, 2025	2
Condensed Consolidated Statements of Cash Flows (Nine Months Ended July 31, 2026 and 2025)	3
Supplemental Data:	
Life Sciences and Diagnostics Markets Segment Results	4
Agilent CrossLab Segment Results	5
Applied Markets Segment Results	6
Reconciliations:	
Gross Margin, R&D, SG&A and Interest Income (Expense), Net & Other Income (Expense), Net - GAAP to Non-GAAP (Q3'26 vs Q3'25)	7
Non-GAAP Income from Operations and Operating Margin (Q3'26 vs Q3'25)	8
Net Income & EPS - Trend	9
Core Revenue by Segment (Q3'26 vs Q3'25)	10
Core Revenue by Region (Q3'26 vs Q3'25)	11
Core Revenue by Market (Q3'26 vs Q3'25)	12
Net Debt to Adjusted EBITDA Ratio	13

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share data)
(Unaudited)
PRELIMINARY

	Three Months Ended July 31,		Nine Months Ended July 31,	
	2026	2025	2026	2025
Net revenue	\$ 1,878	\$ 1,738	\$ 5,511	\$ 5,087
Costs and expenses:				
Cost of products and services	836	850	2,533	2,434
Research and development	123	111	366	336
Selling, general and administrative	475	417	1,416	1,281
Total costs and expenses	1,434	1,378	4,315	4,051
Income from operations	444	360	1,196	1,036
Interest income	15	16	43	45
Interest expense	(29)	(28)	(79)	(85)
Other income (expense), net	14	18	56	(3)
Income before taxes	444	366	1,216	993
Provision for income taxes	82	30	210	124
Net income	<u>\$ 362</u>	<u>\$ 336</u>	<u>\$ 1,006</u>	<u>\$ 869</u>
Net income per share:				
Basic	\$ 1.28	\$ 1.18	\$ 3.55	\$ 3.05
Diluted	\$ 1.28	\$ 1.18	\$ 3.55	\$ 3.05
Weighted average shares used in computing net income per share:				
Basic	282	284	283	285
Diluted	283	285	283	285

The preliminary income statement is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except par value and share data)
(Unaudited)
PRELIMINARY

	July 31, 2026	October 31, 2025
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 1,758	\$ 1,789
Accounts receivable, net	1,478	1,487
Inventory	1,117	1,025
Other current assets	340	293
Total current assets	4,693	4,594
Property, plant and equipment, net	2,134	2,023
Goodwill	5,030	4,473
Other intangible assets, net	906	445
Long-term investments	130	133
Other assets	1,074	1,059
Total assets	<u>\$ 13,967</u>	<u>\$ 12,727</u>
LIABILITIES AND EQUITY		
Current liabilities:		
Accounts payable	\$ 608	\$ 570
Employee compensation and benefits	423	443
Deferred revenue	640	624
Short-term debt	304	304
Other accrued liabilities	314	406
Total current liabilities	2,289	2,347
Long-term debt	3,645	3,050
Retirement and post-retirement benefits	128	126
Other long-term liabilities	542	463
Total liabilities	6,604	5,986
Total Equity:		
Stockholders' equity:		
Preferred stock; \$0.01 par value; 125,000,000 shares authorized; none issued and outstanding	—	—
Common stock; \$0.01 par value, 2,000,000,000 shares authorized; 281,965,813 shares at July 31, 2026 and 283,054,377 shares at October 31, 2025, issued and outstanding	3	3
Additional paid-in-capital	5,681	5,575
Retained earnings	1,912	1,389
Accumulated other comprehensive loss	(233)	(226)
Total stockholders' equity	7,363	6,741
Total liabilities and stockholders' equity	<u>\$ 13,967</u>	<u>\$ 12,727</u>

The preliminary balance sheet is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY

	Nine Months Ended	
	July 31, 2026	July 31, 2025
Cash flows from operating activities:		
Net income	\$ 1,006	\$ 869
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	200	217
Share-based compensation	105	102
Deferred taxes expense (benefit)	77	(35)
Excess and obsolete inventory related charges	35	30
Net (gain) loss on equity securities	2	28
Asset impairment charges	—	15
Other non-cash (income) expense, net	12	4
Changes in assets and liabilities:		
Accounts receivable, net	16	(44)
Inventory	(110)	(72)
Accounts payable	41	(13)
Employee compensation and benefits	(25)	(26)
Other assets and liabilities	(295)	(61)
Net cash provided by operating activities ^(a)	1,064	1,014
Cash flows from investing activities:		
Payments to acquire property, plant and equipment	(249)	(314)
Proceeds from sale of equity securities	—	5
Proceeds from convertible note	—	2
Payments in exchange for convertible note	(3)	(1)
Payments to acquire businesses and intangible assets, net of cash acquired	(950)	4
Net cash used in investing activities	(1,202)	(304)
Cash flows from financing activities:		
Proceeds from issuance of common stock under employee stock plans	63	60
Payment of taxes related to net share settlement of equity awards	(31)	(28)
Payments for repurchase of common stock	(295)	(340)
Payment of excise taxes related to repurchases of common stock	(3)	(10)
Payments of dividends	(216)	(212)
Proceeds from issuance of long-term debt	600	4
Repayments of long-term debt	(4)	(2)
Payments of debt issuance costs	(5)	—
Net proceeds from (repayment of) short-term debt	—	13
Payments of finance lease	(4)	—
Net cash provided by (used in) financing activities	105	(515)
Effect of exchange rate movements	2	10
Net increase (decrease) in cash, cash equivalents and restricted cash	(31)	205
Cash, cash equivalents and restricted cash at beginning of period	1,791	1,332
Cash, cash equivalents and restricted cash at end of period	<u>\$ 1,760</u>	<u>\$ 1,537</u>
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:		
Cash and cash equivalents	\$ 1,758	\$ 1,535
Restricted cash, included in other assets	2	2
Total cash, cash equivalents and restricted cash	<u>\$ 1,760</u>	<u>\$ 1,537</u>

^(a) Cash payments included in operating activities:

Income tax payments, net of refunds received	\$ 376	\$ 304
Interest payments, net of capitalized interest	\$ 47	\$ 55
Net change in property, plant and equipment included in accounts payable and accrued liabilities-increase (decrease)	\$ (9)	\$ -
Excise tax on share repurchases, accrued but not paid	\$ 2	\$ 2

The preliminary cash flow is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
LIFE SCIENCES AND DIAGNOSTICS MARKETS SEGMENT
(Unaudited)
PRELIMINARY

(In millions, except margins data)

	FY26				
	Q1	Q2	Q3	Q4	Total
Net revenue	\$ 679	\$ 732	\$ 746		
Gross margin %	50.5%	54.1%	55.5%		
Income from operations	\$ 109	\$ 161	\$ 176		
Operating margin %	16.0%	22.0%	23.5%		

	FY25				
	Q1	Q2	Q3	Q4	Total
Net revenue	\$ 647	\$ 654	\$ 670	\$ 755	\$ 2,726
Gross margin %	52.8%	52.8%	50.5%	52.9%	52.3%
Income from operations	\$ 117	\$ 129	\$ 118	\$ 172	\$ 536
Operating margin %	18.1%	19.7%	17.6%	22.7%	19.7%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and net (gain) loss on equity securities.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
AGILENT CROSSLAB SEGMENT
(Unaudited)
PRELIMINARY

(In millions, except margins data)

	FY26				
	Q1	Q2	Q3	Q4	Total
Net revenue	\$ 758	\$ 759	\$ 786		
Gross margin %	55.2%	55.5%	57.0%		
Income from operations	\$ 240	\$ 242	\$ 270		
Operating margin %	31.6%	32.0%	34.3%		

	FY25				
	Q1	Q2	Q3	Q4	Total
Net revenue	\$ 696	\$ 713	\$ 744	\$ 755	\$ 2,908
Gross margin %	56.1%	55.5%	55.1%	54.9%	55.4%
Income from operations	\$ 221	\$ 231	\$ 248	\$ 246	\$ 946
Operating margin %	31.8%	32.4%	33.3%	32.5%	32.5%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and net (gain) loss on equity securities.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
APPLIED MARKETS SEGMENT
(Unaudited)
PRELIMINARY

(In millions, except margins data)

	FY26				
	Q1	Q2	Q3	Q4	Total
Net revenue	\$ 361	\$ 344	\$ 346		
Gross margin %	56.5%	55.8%	57.3%		
Income from operations	\$ 93	\$ 80	\$ 86		
Operating margin %	25.8%	23.3%	24.9%		

	FY25				
	Q1	Q2	Q3	Q4	Total
Net revenue	\$ 338	\$ 301	\$ 324	\$ 351	\$ 1,314
Gross margin %	55.8%	53.5%	53.6%	54.6%	54.4%
Income from operations	\$ 84	\$ 59	\$ 71	\$ 87	\$ 301
Operating margin %	25.0%	19.5%	21.8%	24.7%	22.9%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and net (gain) loss on equity securities.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF NON-GAAP AND GAAP FINANCIAL RESULTS
(In millions, except margin data)
(Unaudited)
PRELIMINARY

<u>GROSS MARGIN</u>	<u>Q3'26</u>	<u>Gross Margin %</u>		<u>Q3'25</u>	<u>Gross Margin %</u>
GAAP revenue:	\$ 1,878			\$ 1,738	
Gross margin:					
GAAP cost of products and services	\$ 836	55.5%	(a)	\$ 850	51.1%
Non-GAAP adjustments:					
Restructuring and other related costs	(2)			(7)	
Intangible amortization	(10)			(16)	
Transformational initiatives	(1)			—	
Acquisition and integration costs	(3)			—	
Other	(2)			(11)	
Non-GAAP cost of products and services	\$ 818	56.4%	(a)	\$ 816	53.1%

<u>RESEARCH & DEVELOPMENT EXPENSES</u>	<u>Q3'26</u>	<u>R&D as % of Revenue</u>		<u>Q3'25</u>	<u>R&D as % of Revenue</u>
GAAP revenue:	\$ 1,878			\$ 1,738	
GAAP research and development expenses	\$ 123	6.5%		\$ 111	6.4%
Non-GAAP adjustments:					
Restructuring and other related costs	(3)			—	
Transformational initiatives	(1)			—	
Acquisition and integration costs	—			(1)	
Other	(1)			—	
Non-GAAP research and development expenses	\$ 118	6.3%		\$ 110	6.3%

<u>SELLING, GENERAL & ADMINISTRATIVE EXPENSES</u>	<u>Q3'26</u>	<u>SG&A as % of Revenue</u>		<u>Q3'25</u>	<u>SG&A as % of Revenue</u>
GAAP revenue:	\$ 1,878			\$ 1,738	
GAAP selling, general and administrative expenses	\$ 475	25.3%		\$ 417	24.0%
Non-GAAP adjustments:					
Restructuring and other related costs	(10)			(10)	
Intangible amortization	(11)			(10)	
Transformational initiatives	(35)			(18)	
Acquisition and integration costs	(4)			(2)	
Other	(5)			(2)	
Non-GAAP selling, general & administrative expenses	\$ 410	21.8%		\$ 375	21.6%

<u>INTEREST INCOME (EXPENSE), NET AND OTHER INCOME (EXPENSE), NET</u>	<u>Q3'26</u>		<u>Q3'25</u>
GAAP interest income (expense), net and other income (expense), net	—		\$ 6
Non-GAAP adjustments:			
Net (gain) loss on equity securities	5		1
Other	—		(1)
Non-GAAP interest income (expense), net and other income (expense), net	\$ 5		\$ 6

(a) GAAP and non-GAAP gross margin of 55.5% and 56.4% includes approximately 160 basis points related to net benefit from tariff refunds.

We provide non-GAAP gross margin, research & development, selling, general & administrative expense, and interest income (expense), net and other income (expense), net amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and net (gain) loss on equity securities.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of gross margin, research & development, selling, general & administrative expense, and interest income (expense), net and other income (expense), net is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF NON-GAAP INCOME FROM OPERATIONS AND OPERATING MARGIN
(In millions, except margin data)
(Unaudited)
PRELIMINARY

	Q3'26	Operating Margin %		Q3'25	Operating Margin %	Year Over Year Percent Pts Inc/(Dec)
GAAP revenue:	\$ 1,878			\$ 1,738		
Income from operations:						
GAAP Income from operations	\$ 444	23.6%	^(a)	\$ 360	20.7%	
Non-GAAP adjustments:						
Restructuring and other related costs	15			17		
Intangible amortization	21			26		
Transformational initiatives	37			18		
Acquisition and integration costs	7			3		
Other	8			13		
Non-GAAP income from operations	<u>\$ 532</u>	28.3%	^(a)	<u>\$ 437</u>	25.1%	3.2%

^(a) GAAP and non-GAAP income from operations of \$444 million and \$532 million, respectively, includes a \$20 million net benefit from tariff refunds. GAAP and non-GAAP operating margin of 23.6% and 28.3% includes a 110 basis points net benefit from tariff refunds.

We provide non-GAAP income from operations and non-GAAP operating margin amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, amortization of intangibles, transformational initiatives and acquisition and integration costs.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of income from operations and operating margins is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share data)
(Unaudited)
PRELIMINARY

	Q3'25		Q4'25		Q1'26		Q2'26		Q3'26	
	Net income	Diluted EPS	Net income	Diluted EPS	Net income	Diluted EPS	Net income	Diluted EPS	Net income	Diluted EPS
GAAP net income	\$ 336	\$ 1.18	\$ 434	\$ 1.53	\$ 305	\$ 1.07	\$ 339	\$ 1.20	\$ 362	\$ 1.28
Non-GAAP adjustments:										
Restructuring and other related costs	17	0.06	8	0.03	20	0.07	8	0.03	15	0.05
Intangible amortization	26	0.09	23	0.08	19	0.07	19	0.07	21	0.07
Transformational initiatives	18	0.06	21	0.07	19	0.07	39	0.14	37	0.13
Acquisition and integration costs	3	0.01	4	0.01	3	0.01	12	0.04	7	0.02
Net (gain) loss on equity securities	1	—	11	0.04	—	—	1	—	5	0.02
Pension settlement loss	—	—	1	—	—	—	—	—	—	—
Other	12	0.05	5	0.02	27	0.09	7	0.02	8	0.03
Adjustment for taxes ^(a)	(23)	(0.08)	(55)	(0.19)	(7)	(0.02)	(2)	(0.01)	4	0.02
Non-GAAP net income	<u>\$ 390</u>	<u>\$ 1.37</u>	<u>\$ 452</u>	<u>\$ 1.59</u>	<u>\$ 386</u>	<u>\$ 1.36</u>	<u>\$ 423</u>	<u>\$ 1.49</u>	<u>\$ 459</u>	<u>\$ 1.62</u>

^(a) The adjustment for taxes excludes tax expense (benefits) that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as the realized gain/loss due to sale of a business, windfall benefits on stock compensation, and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017 which does not apply for fiscal year 2026 due to the enactment of the One Big Beautiful Bill Act (OBBBA). During the three months ended July 31, 2025, tax reserves were released, which resulted in a tax benefit for GAAP purposes. This tax benefit is excluded from our non-GAAP results since it is not related to on-going business operations. During the three months ended October 31, 2025, an intra-entity transfer of assets along with the release of tax reserves resulted in a tax benefit for GAAP purposes. This tax benefit is excluded from our non-GAAP results since it is not related to on-going business operations. For the three months ended July 31, 2025 and October 31, 2025, management used a non-GAAP effective tax rate of 12.00%. For the three months ended January 31, 2026, April 30, 2026 and July 31, 2026, management used a non-GAAP effective tax rate of 14.50%.

^(b) GAAP and Non-GAAP net income of \$362 million and \$459 million, respectively, includes a \$17 million net benefit from tariff refunds. GAAP and Non-GAAP EPS of \$1.28 and \$1.62, respectively, includes a \$0.06 net benefit from tariff refunds.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, amortization of intangibles, transformational initiatives, acquisition and integration costs, net (gain) loss on equity securities and pension settlement loss.

Restructuring and other related costs include incremental expenses incurred in the period associated with restructuring programs, usually aimed at changes in business and/or cost structure. Such costs may include one-time termination benefits including acceleration of stock-based compensation expense, facility-related costs and contract termination fees.

Intangible amortization refers to the systematic expensing of the cost of finite lived intangible assets over their estimated useful lives. Such assets, which include acquired patents, trademarks, customer lists, and other identifiable intangibles, are amortized to match the pattern in which their economic benefits are consumed. If the useful life is not reliably determinable, amortization is calculated on a straight line basis over the best estimate of that life.

Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system and human resources and financial systems.

Acquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, tax, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

Net (gain) loss on equity securities relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities.

Pension settlement loss relates to the relief of the US Retirement Plan pension obligation due to increased lump sum payouts over a specified accounting threshold.

Other includes certain legal costs and settlements, consulting costs, special compliance costs, acceleration of stock-based compensation expense, impact of the difference between current and inflated tariff rates between USA and China for the first two weeks of May 2025 and other miscellaneous adjustments.

Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results "through the eyes" of management in addition to seeing our GAAP results. This information facilitates our management's internal comparisons to our historical operating results as well as to the operating results of our competitors.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
RECONCILIATIONS OF REVENUE BY SEGMENT
EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(in millions)
(Unaudited)
PRELIMINARY

		Year-over-Year		
		GAAP		
		Q3'26	Q3'25	Year-over-Year % Change
GAAP Revenue by Segment				
Life Sciences and Diagnostics Markets Segment	\$	746	\$ 670	11%
Agilent CrossLab Segment		786	744	6%
Applied Markets Segment		346	324	7%
Agilent	\$	1,878	\$ 1,738	8%

		Non-GAAP (excluding Acquisitions & Divestitures)			Year-over-Year at Constant Currency ^(a)		Current Quarter Currency Impact ^(b)
		Q3'26	Q3'25	Year-over-Year % Change	Year-over-Year % Change	Percentage Point Impact from Currency	
Non-GAAP Revenue by Segment							
Life Sciences and Diagnostics Markets Segment	\$	736	\$ 670	10%	10%	—	\$ 1
Agilent CrossLab Segment		786	744	6%	5%	1 ppt	2
Applied Markets Segment		346	324	7%	7%	—	1
Agilent (Core)	\$	1,868	\$ 1,738	8%	7%	1 ppt	\$ 4

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

^(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

^(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
RECONCILIATIONS OF REVENUE BY REGION
EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(in millions)
(Unaudited)
PRELIMINARY

	Year-over-Year			
	GAAP			
	Q3'26	Q3'25	Year-over-Year % Change	
<u>GAAP Revenue by Region</u>				
Americas	\$ 761	\$ 683	12%	
Europe	504	492	2%	
Asia Pacific	613	563	9%	
Total Revenue	<u>\$ 1,878</u>	<u>\$ 1,738</u>	8%	
China and Hong Kong	\$ 346	\$ 304	14%	

	Non-GAAP (excluding Acquisitions & Divestitures)			Year-over-Year at Constant Currency ^(a)		
	Q3'26	Q3'25	Year-over-Year % Change	Year-over-Year % Change	Percentage Point Impact from Currency	Current Quarter Currency Impact ^(b)
<u>Non-GAAP Revenue by Region</u>						
Americas	\$ 751	\$ 683	10%	10%	—	\$ 3
Europe	504	492	2%	2%	—	4
Asia Pacific	613	563	9%	9%	—	(3)
Total Revenue (Core)	<u>\$ 1,868</u>	<u>\$ 1,738</u>	8%	7%	1 ppt	<u>\$ 4</u>
China and Hong Kong	\$ 346	\$ 304	14%	9%	5 pts	\$ 13

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

^(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

^(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
RECONCILIATIONS OF REVENUE BY MARKET
EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(in millions)
(Unaudited)
PRELIMINARY

	Year-over-Year		
	GAAP		
	Year-over-Year		
<u>GAAP Revenue by Market</u>	Q3'26	Q3'25	% Change
Pharmaceutical and biotechnology	\$ 707	\$ 629	13%
Academia and government	128	132	(3%)
Diagnostics and clinical	284	258	10%
Chemicals and advanced materials	430	399	8%
Food	158	157	—
Environmental and forensics	171	163	5%
Total Revenue	<u>\$ 1,878</u>	<u>\$ 1,738</u>	8%

	Non-GAAP (excluding Acquisitions & Divestitures)			Year-over-Year at Constant Currency ^(a)		
	Year-over-Year			Year-over-Year	Percentage Point	Current Quarter
<u>Non-GAAP Revenue by Market</u>	Q3'26	Q3'25	% Change	% Change	Impact from Currency	Currency Impact ^(b)
Pharmaceutical and biotechnology	\$ 707	\$ 629	13%	12%	1 ppt	\$ 1
Academia and government	128	132	(3%)	(3%)	—	—
Diagnostics and clinical	274	258	6%	6%	—	1
Chemicals and advanced materials	430	399	8%	7%	1 ppt	1
Food	158	157	—	—	—	—
Environmental and forensics	171	163	5%	5%	—	1
Total Revenue (Core)	<u>\$ 1,868</u>	<u>\$ 1,738</u>	8%	7%	1 ppt	<u>\$ 4</u>

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

^(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

^(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
NET DEBT TO ADJUSTED EBITDA CALCULATION
(in millions, except ratio data)
(Unaudited)
PRELIMINARY

	As of
	July 31, 2026
Long-term debt	\$ 3,645
Short-term debt	304
Cash & cash equivalents	(1,758)
Net debt	\$ 2,191

	Q4'25	Q1'26	Q2'26	Q3'26	Trailing 12-Month
GAAP net income	\$ 434	\$ 305	\$ 339	\$ 362	\$ 1,440
Non-GAAP adjustments:					
Restructuring and other related costs	8	20	8	15	51
Intangible amortization	23	19	19	21	82
Transformational initiatives	21	19	39	37	116
Acquisition and integration costs	4	3	12	7	26
Pension settlement loss	1	—	—	—	1
Net (gain) loss on equity securities	11	—	1	5	17
Other	5	27	7	8	47
Adjustment for taxes	(55)	(7)	(2)	4	(60)
Non-GAAP net income	\$ 452	\$ 386	\$ 423	\$ 459	\$ 1,720
Add:					
(1) Net interest expense	\$ 10	\$ 10	\$ 12	\$ 14	\$ 46
GAAP provision for income taxes	8	59	69	82	218
Adjustment for taxes	55	7	2	(4)	60
(2) Non-GAAP provision for income taxes	\$ 63	\$ 66	\$ 71	\$ 78	\$ 278
(3) Depreciation expense	\$ 48	\$ 48	\$ 48	\$ 45	\$ 189
Adjusted EBITDA					\$ 2,233
Net debt to adjusted EBITDA ratio					1.0

The preliminary net debt to adjusted EBITDA ratio is estimated based on our current information.